Concepedia

Author

Mauro Romanenghi

European Institute of Oncology

Also Known As

M Romanenghi, M. Romanenghi, Mauro Romanenghi

13

Publications

569

Citations

9

H-Index

35

Concepts

All Affiliations

European Institute of OncologyUniversity of MilanUniversity of Naples Federico IIIFOMIstituti di Ricovero e Cura a Carattere Scientifico
MR

About

Mauro Romanenghi is an author at European Institute of Oncology specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

437

2

Natural Sciences

3

3

354

3

Cell Biology

3

3

73

4

Biochemistry

1

1

283

5

Chemical Biology

1

1

283

Mauro Romanenghi

×

9

Publications

558

Citations

9

H-Index

YearCitations

Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2

Claudia Binda, Sérgio Valente, Mauro Romanenghi,

Journal of the American Chemical Society

2010

283

Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia

Sadia Saeed, Colin Logie, Kees-Jan Francoijs,

Blood

2012

65

NA-Seq: A Discovery Tool for the Analysis of Chromatin Structure and Dynamics during Differentiation

Gaetano Gargiulo, Samuel Lévy, Gabriele Bucci,

Developmental Cell

2009

54

CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer

Maria Grazia Filippone, Daniela Gaglio, R. Bonfanti,

Nature Communications

2022

43

The DNA demethylating agent decitabine activates the TRAIL pathway and induces apoptosis in acute myeloid leukemia

Matías Soncini, Fabio Santoro, Arantxa Gutiérrez,

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

2012

31

Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models

Martina Menna, Francesco Fiorentino, Biagina Marrocco,

European Journal of Medicinal Chemistry

2022

27

HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia

Parinaz Mehdipour, Fabio Santoro, Oronza A. Botrugno,

Leukemia

2017

25

Quantitative Chemical Proteomics Identifies Novel Targets of the Anti-cancer Multi-kinase Inhibitor E-3810

Mara Colzani, Roberta Noberini, Mauro Romanenghi,

Molecular & Cellular Proteomics

2014

17

Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibition

Riccardo Cazzoli, Francesco Romeo, Isabella Pallavicini,

Cell Reports

2023

13

Page 1